An experimental drug, LX211 (LUVENIQ™; oral voclosporin), may become the first approved oral treatment capable of modifying the course of uveitis, a group of serious eye conditions inevitably associated with either severe vision loss or substantial morbidity from steroid use. Results of international Phase 2/3 clinical trials conducted by Lux Biosciences, to be the subject [...]

Trial reports of the Evolife range of products in France have pointed to significant benefits and enhanced quality of life for cancer patients who use the products before, during and after chemo or radiotherapy treatment. Evolife is a natural range of cosmetics that is 100% dedicated to the support care of cancer patients.